Adam F can be very misleading. He claims Brandicourt pulled Exubera while at Pfizer. Very far from the truth. Jeff Kindler, the Pfizer CEO, an Attorney pulled Exubera to the objections of Brandicourt. Brandicourt resigned from Pfizer shortly after that to join Bayer. Bayer was one of the bidders for Afrezza and brandicourt was the head of that group. Go figure.
Shorts bet Dilution was coming - 50M shares short
Shorts bet that the Adcom will vote Afreeza down - 60M short volume
Shorts bet the FDA will not approve Afrezza - 70M short volume
Shorts are betting Afrezza wil fail in the market - 90M shares short
I'll tell you why they are really shorting. They are selling shares to get the cash to pay off their banks and cocover for other losses. It's a Ponzi Scheme. It's not about anything rationale other than that's the only thing they can get away with. The only time they fold will be either BK or pps takes off and they are forced to cover. But cover for any rationale reason - they can't because they don't have the cash to buy the shares. They'll have to sell short something else to raise the cash but their bankers won't allow that unless they liquidate other short position.
So stop thinking why shorts are shorting more. A Ponzi Scheme has no other way to go.
If you are asking me, I know because of 25 years in Pharma and I was with one of the companies I mentioned. Jeff Kindler was pfizer's general counsel. He was promoted to CEO and his first task was to cut costs. Pfizer had no other diabetes product. Nor does it know anything about medical devices such as an bulky inhaler. Wanting to focus on its core competence, all the outlier products were cut, Exhubera being one of them. Under brandicourt, Pfizer was very optimistic about Exubera. So positive they bought SAnofi's share of Exubera for $1.3B. But with Barndicourt's exit, everything well to the way side. Here's his chance for a comeback with an inhable insulin. Wouldn't surprise me if it was one of the reasons why he jumped from bayer to Sanofi.
factspls, sorry I have no access to script volumes. I only write in areas that I am familiar with. IMS scripts is not one of them. Delayed at best by 2 weeks and only a statistical sample size (I worked at IMS, so I should know). It is not as scientific as they are making people think. They (IMS) buy from a select contracted vendors and use statistical algorithms to forecast the predicted number based on a number of variables. Afrezza being new, they won't have historical information to work with. In addition, the largest pharmacies do not sell their data anymore, preferring to package it themselves and selling them to pharmas directly. Walmart, CVS, etc. won't be in that IMS script. So the script info you are hearing about is just a wild guess, and anybody;s guess.
mike, not only did SNY ask that Medtone be replaced, at about the same time they sold their EU rights for Exubera to Pfizer. This was in realization that Exubera, even if Pfizer kept selling it would just be wiped out by Afrezza. Sanofi also bought the former Exhubera plant in France. WHY? If they have no powdered insulin what would they need a plant designed for producing powdered insulin? All that are indicators of their long term commitment to Afrezza.
A letter to their investors? Why? Are they planning on asking their investors to approve something BIG related to Afrezza??
If the shorts have over 200M shares short, do they get control of the company? Bwahhhhh!!!! They can short 400M shares and they can't get a seat on the board. They keep guessing wrong. Why would they be right now?
That's very good news. PPS going up while short volume going up. Poor suckers pouring in cheap shares being bought up easily.
william_gustinberg: "Most would agree that short sellers are much more experience and savvy than the average investor"
You mean the same shorts that shorted 70M shares that the FDA won't approve Afrezza? You call that smarter and savier? Speak for your own I.Q.
opc, I am disappointed with your shallow analysis. You know all expenses (your $120M operating expense) is reimbursed by Sanofi as Cost of Goods. You also know that "convertible debt" has mostly been converted. So what's left in your statement that is remotely correct?
trade-pro, you are obviously a fake. No Canadian will cross over to buy prescription drugs in the U.S.. first of all you need a prescription. Second, you will have to pay cash since you don't have insurance in the U.S. And what Canadian actually pays for their medication when it is FREE in Canada. Lastly, Canadians do not cross the border and shop in Buffalo. They cross the border and shop in Niagara!! Busted.
very cool. It is available for $285.54 in the nearest Target, CVS, WAl-Mart, and even a local pharmacy that has only 1 store. It is all over the place now. You should try it if you have any doubt. It is available now at your nearest drugstore.
Good. We could use the publicity Would make good news. Loser shorts vs satisfied customer. Guess who the public will side with
It's possible. When a founding ceo steps aside it is a signal for all deals tol be considered. They are free to sell themselves. SNY will be forced to make an offer or lose Afrezza to another big pharma. that type of deal happens a lot in the pharma industry. Example, Onyx partnered with Bayer. When Bayer did not buyout Onyx, they sold themselves to Amgen. So now Bayer has to work with Amgen until Amgen pulls the plug on Bayer
Problem is, the shorts are running a Ponzi scheme. They sell short to use the cash to cover other losses. They don't have the money to cover. So you can keep warning them all you want. They won't cover because they can't!
Good call. There was a hint - when Jim Cramer yells SELL and Adam F writes a bash article all within two days - you know they are desperados. With Jason Karp's failure. Jim Cramer has to step up. Tsk Tsk Tsk. It will go to 100M shares and the pps will be up instead of down.
The jokes on GS. Whoever pulled this stunt must be nursing a whiplash. They're busy counting their losses. Sell low buy high. TThat was not the plan. Just amazing how much wall street is just pure gambling. There's no investment going on, just pure manipulation for profit.
OK here's one fact you can't argue - the Lantus/Afrezza Combo Patent. It takes two years to get a patent approvedand about 6 months to prepare a patent. The patent was approved in 2010. So you are looking at 2007 collaboration to acquire the patent. Is that enough proof for you?
He also said the former CEO's job is not in jeopardy, just days before they canned him. I agree with the posters here. The fact that he stated this means he is willing to negotiate for an acquisition.